LONDON (Alliance News) - Pharmaceutical development firm Nuformix PLC on Monday reported positive results from its completed NXP002 fibrosis programme pre-clinical trial for the treatment of idiopathic pulmonary fibrosis, a type of lung condition.
In multi-patient tissue studies performed in partnership with Newcastle University, data indicated that NXP002 candidates strongly inhibit fibrosis ex-vivo, or outside of an organism, giving strong support for treating idiopathic pulmonary fibrosis and other lung conditions.
In addition, trials showed NXP002 outperformed the current standard of care treatment, Esbriet.
Nuformix will now look to optimise the delivery of a candidate within its NXP002 programme to maximise the efficacy and tolerability using its novel drug forms for conducting patient studies.
"Despite the advent of new treatments, life expectancy has not really changed for patients diagnosed with IPF. Few patients respond to current treatments and have to tolerate severe side effects that dramatically impact quality of life - severe vomiting on one therapy or severe diarrhoea on the other. This promising data gives us confidence in our ability to both inhibit fibrosis and attenuate inflammation in patients without these side effects," said Chief Executive Dan Gooding.
Shares in Nuformix were up 1.9% at 2.65 pence on Monday.
Nuformix (NFX)